Drug Search Results
More Filters [+]

Cepeginterferon alfa-2b

Alternative Names: cepeginterferon alfa-2b
Latest Update: 2018-08-09
Latest Update Note: Clinical Trial Update

Product Description

For Treatment of Chronic Hepatitis C (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01740089)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biocad
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cepeginterferon alfa-2b

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hepatitis A|Hepatitis C, Chronic|HIV Infections|Coinfection|Acquired Immunodeficiency Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BCD-016-3

P3

Completed

Hepatitis A|Hepatitis C, Chronic

2015-12-02

44%

BCD-016-4

P3

Completed

Hepatitis A|Coinfection|Hepatitis C, Chronic|Acquired Immunodeficiency Syndrome|HIV Infections

2015-08-26

PEG-IFNа-2

P3

Completed

Hepatitis A|Hepatitis C, Chronic

2012-07-01

Recent News Events

Date

Type

Title